Form D · Biotechnology
Pulmatrix, Inc.
Framingham, MA · CIK 0001574235
Offering snapshot reported Apr 15, 2026 · SEC filing
- Reported sold
- $1M Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $1M Reported outside-investor minimum
- First sale
- Mar 26, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 15, 2026 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jul 20, 2021 | Initial | $45,000 | No comparison | Not reported | SEC filing |
| Feb 23, 2021 | Initial | $0 | No comparison | 5 | SEC filing |
| Jul 20, 2020 | Initial | $0 | No comparison | 5 | SEC filing |
| Apr 24, 2020 | Initial | $8,070,723 | No comparison | 3 | SEC filing |
| Feb 14, 2019 | Initial | $2,489,820 | No comparison | 7 | SEC filing |
| Feb 14, 2019 | Initial | $73,531 | No comparison | 1 | SEC filing |
| Feb 14, 2019 | Initial | $21,565 | No comparison | 1 | SEC filing |
| Dec 18, 2018 | Initial | $3,656,250 | No comparison | 1 | SEC filing |
| Jun 30, 2015 | Initial | $935,000 | No comparison | 1 | SEC filing |
| Jun 30, 2015 | Initial | $687,500 | No comparison | 3 | SEC filing |
| Jun 30, 2015 | Initial | $21,383,416 | No comparison | 12 | SEC filing |
| Jun 30, 2015 | Initial | $0 | No comparison | 1 | SEC filing |
| Jun 16, 2015 | Initial | $2,608,276 | No comparison | 34 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-580597
The issuer issued 1,000 shares of Series B Convertible Preferred Stock, stated value $1,000 per share for aggregate proceeds of $1,000,000 in a private placement pursuant to Rule 506(b) of Regulation D.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Apr 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Akihisa Akao | Director |
| Hojabr Alimi | Executive, Promoter |
| Richard Batycky | Director |
| Todd Bazemore | Director |
| Christopher Cabell | Director |
| Robert Clarke | Director, Executive |
| Richard Conley | Director, Promoter |
| William Duke | Executive |
| Gregory French | Director, Promoter |
| Steven Gillis | Director |
| Kurt Graves | Director |
| Sameer Harish | Executive, Promoter |
| David Hava | Executive |
| Michael Higgins | Director |
| Mark Iwicki | Director |
| Peter Ludlum | Executive |
| David Maki | Director |
| Terrance Mc Guire | Director |
| Amit D. Munshi | Director |
| . Oculus Innovative Sciences, Inc. | Promoter |
| Teofilo Raad | Director, Executive |
| James Roach | Executive |
| Scott Rocklage | Director |
| Matthew Sherman | Director |
| Michelle S. Siegert | Executive |
| Anand Varadan | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
945 Concord Street Suite 1217
Framingham, MA, 01701
Framingham, MA, 01701